HALOZYME THERAPEUTICS, INC. (HALO)
CIK 1159036 · all EDGAR filings →
Same rating bands the category standard uses, but free, with the formula on the chip and the gaps in the data said out loud.
Shares outstanding over time
Latest: 113.5M shares as of Jul 31, 2026 (10-Q). Share count fell from 127.3M to 12.8M between May 6, 2015 and Aug 6, 2015, a pattern consistent with a reverse split (roughly 1-for-10); simultaneous issuance can skew the raw ratio, so confirm in the filings. The red bar marks the cliff.
Cash runway
Self-funding
profitable · generates cash
Full breakdown: cash runway tool · source filing →
Warrants
No warrant figures tagged in this filer’s XBRL facts. That means the company has not reported them in structured form; it does not prove no warrants exist. The exhibits are the ground truth.
Convertible notes
| Note | Principal | Carrying | Conv. price | Rate | If converted |
|---|---|---|---|---|---|
| 0.00 Convertible Senior Notes Due 2031 | $750.0M | $736.4M | $87.2 | 0% | ~8.6M sh |
| 0.875 Convertible Senior Notes Due 2032 | $750.0M | $735.8M | $87.2 | 0.875% | ~8.6M sh |
| 100 Convertible Senior Notes Due 2028 | $470.0M | $465.5M | $56.02 | 1% | ~8.4M sh |
| 0.25 Convertible Senior Notes Due 2027 | $209.6M | $209.0M | $77.17 | 0.25% | ~2.7M sh |
If every note above converted at its tagged price: ~28.3M new shares on 113.5M currently outstanding. An estimate from principal ÷ conversion price, with inputs carrying different as-of dates; make-whole adjustments, capped calls and partial repurchases are not modeled.
Notes exactly as the company dimensioned them in its 10-Q filed Aug 6, 2026 →. Principal is face amount as tagged, not what remains after repurchases unless the filer updated the tag. A note the filer did not dimension is absent here, not absent from the balance sheet; the exhibits stay the ground truth.
Fully diluted build-up
Shares outstanding plus every potential-share instrument the filer tagged in XBRL, each at its own as-of date. An estimate assembled from filed figures, not a filing figure itself.
| Shares outstanding | 113.5M | Jul 31, 2026 |
| + 0.00 Convertible Senior Notes Due 2031 (if fully converted) | 8.6M | Jun 30, 2026 |
| + 0.875 Convertible Senior Notes Due 2032 (if fully converted) | 8.6M | Jun 30, 2026 |
| + 100 Convertible Senior Notes Due 2028 (if fully converted) | 8.4M | Jun 30, 2026 |
| + 0.25 Convertible Senior Notes Due 2027 (if fully converted) | 2.7M | Jun 30, 2026 |
| Fully diluted estimate | 141.8M | +24.9% vs O/S |
Still excluded, because the filer does not tag them in countable form: employee options and RSUs, any instrument living only in exhibit prose, and instruments above missing a share count. Inputs carry different as-of dates, shown per row. Each figure traces to the tranche and note tables above and their cited filings.
Registrations and offerings
Last 12 months: 1 executed · 0 registered.
Full history and shelf status: offering checker · S-3 shelf checker
Source: SEC EDGAR XBRL company facts and filing metadata, fetched live and cached briefly. Share counts are cover-page figures with their form named. Warrant tranches and convertible notes come from the dimensioned facts in the latest 10-Q/10-K instance document, exactly as the company tagged them; untagged tranches and notes are absent, not disproven. Nothing on this page is manually verified and nothing is behind a login: what free data supports is shown, what it cannot support is stated. Not investment advice.
Keep going: float checker · offering calendar · short-squeeze screener · full HALO workspace